PUBLISHER: IMARC | PRODUCT CODE: 1451541
PUBLISHER: IMARC | PRODUCT CODE: 1451541
The global prefilled syringes market size reached US$ 7.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 15.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032.
A prefilled syringe is a single-dose packet of injectable vaccines that is disposable in nature. The usage of prefilled syringes significantly lowers the chances of drug contamination as it avoids the potential admixture-related contamination risks when syringes are inserted into a drug vial to draw out a dose. Combining this with a pre-sterilized syringe further increases safety, enables the easy and quick delivery of drugs in the case of emergencies, and eliminates the additional on-site vial cleaning and de-pyrogenation processes. Consequently, they are a preferred option to administer the drugs via the parenteral route for delivering a wide range of injectables, such as biosimilar and biologics.
The global market is primarily driven by the increasing incidences of chronic diseases, including diabetes and autoimmune diseases. This is further supported by the growing demand for treating chronic medical conditions using biological drugs in pre-fillable syringes. In addition to this, the widespread adoption of the prefilled syringe products by healthcare professionals and the escalating number of new product launches by key players are also fostering the market. Moreover, with significant technological advancements, the implementations of self-injecting parenteral devices are also increasing, which, in turn, is contributing to the market growth. The market is also driven by the rising geriatric population on the global level and growing investments in improving the overall healthcare infrastructure. Other factors, such as supportive government regulations regarding needlestick legislation, the rising consciousness regarding the advantages of prefilled syringes, the widespread preference for home-based healthcare, and the increasing popularity of biologics and biosimilars across the pharmaceutical settings, are further creating lucrative growth opportunities in the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global prefilled syringes market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on design, material, closing system, application and end user.
Single-chamber Prefilled Syringes
Dual-chamber Prefilled Syringes
Customized Prefilled Syringes
Glass Prefilled Syringes
Plastic Prefilled Syringes
Staked Needle System
Luer Cone System
Luer Lock Form System
Diabetes
Anaphylaxis
Rheumatoid Arthritis
Oncology
Others
Hospitals
Clinics
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, B. Braun Melsungen AG, Baxter International Inc., Bayer AG, Becton Dickinson and Company, Cardinal Health Inc., Catalent Inc., Fresenius SE & Co. KGaA, Gerresheimer AG, Nipro Corporation, Schott AG, Terumo Corporation and West Pharmaceutical Services Inc.